Skip to main content
. 2019 Feb 18;17(4):920–927. doi: 10.5114/aoms.2019.83000

Figure 1.

Figure 1

Progression-free (A, B) and overall survival (C, D) curves with bendamustine treatment in histological subtypes of relapsed/refractory lymphoma

DLBCL– diffuse large B-cell lymphoma, SLL/CLL – small lymphocytic lymphoma/chronic lymphocytic leukemia.